{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:30:11Z","timestamp":1793939411902,"version":"4.8.0"},"reference-count":10,"publisher":"BMJ","issue":"9","funder":[{"name":"French research agency","award":["ANR-18-RHUS-0012"],"award-info":[{"award-number":["ANR-18-RHUS-0012"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2023,2,7]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec><jats:title>Background and objectives<\/jats:title><jats:p>Neuromyelitis optica spectrum disorders (NMOSDs) are a group of diseases mainly characterised by recurrent optic neuritis and\/or myelitis. Most cases are associated with a pathogenic antibody against aquaporin-4 (AQP4-Ab), while some patients display autoantibodies targeting the myelin oligodendrocyte glycoprotein (myelin oligodendrocyte glycoprotein antibodies (MOG-Abs)). Anti-Argonaute antibodies (Ago-Abs) were first described in patients with rheumatological conditions and were recently reported as a potential biomarker in patients with neurological disorders. The aims of the study were to investigate if Ago-Abs can be detected in NMOSD and to evaluate its clinical usefulness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sera from patients prospectively referred to our centre with suspected NMOSD were tested for AQP4-Abs, MOG-Abs and Ago-Abs with cell-based assays.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The cohort included 104 prospective patients: 43 AQP4-Abs-positive cases, 34 MOG-Abs positive cases and 27 double-negative patients. Ago-Abs were detected in 7 of 104 patients (6.7%). Clinical data were available for six of seven patients. The median age at onset of patients with Ago-Abs was 37.5 [IQR 28.8\u201350.8]; five of six patients tested positive also for AQP4-Abs. Clinical presentation at onset was transverse myelitis in five patients, while one presented with diencephalic syndrome and experienced a transverse myelitis during follow-up. One case presented a concomitant polyradiculopathy. Median EDSS score at onset was 7.5 [IQR 4.8\u20138.4]; median follow-up was 40.3 months [IQR 8.3\u201364.7], and median EDSS score at last evaluation was 4.25 [IQR 1.9\u20135.5].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Ago-Abs are present in a subset of patients with NMOSD and, in some cases, represent the only biomarker of an autoimmune process. Their presence is associated with a myelitis phenotype and a severe disease course.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2022-330707","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T18:21:28Z","timestamp":1677003688000},"page":"738-741","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Anti-Argonaute antibodies as a potential biomarker in NMOSD"],"prefix":"10.1136","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-456X","authenticated-orcid":false,"given":"Sara","family":"Carta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7664-533X","authenticated-orcid":false,"given":"Do","family":"Le Duy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Rogemond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Derache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Chaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Fromont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Cabasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Boudot de la Motte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4721-5952","authenticated-orcid":false,"given":"Jerome","family":"Honnorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Marignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"key":"2024102910301105000_94.9.738.1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1212\/WNL.0000000000002366","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"86","author":"Tan","year":"2016","journal-title":"Neurology"},{"key":"2024102910301105000_94.9.738.2","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00218-0"},{"key":"2024102910301105000_94.9.738.3","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with neuromyelitis optica spectrum disorders: a literature review","volume":"27","author":"Shahmohammadi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2024102910301105000_94.9.738.4","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001145","article-title":"The clinical characteristics of primary sjogren\u2019s syndrome with neuromyelitis optica spectrum disorder in china: a strobe-compliant article","volume":"94","author":"Qiao","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2024102910301105000_94.9.738.5","doi-asserted-by":"publisher","DOI":"10.1186\/ar1987"},{"key":"2024102910301105000_94.9.738.6","doi-asserted-by":"crossref","unstructured":"Chan EKL , Fritzler MJ . Ten years of progress in GW\/P body research. New York, NY, 2013. doi:10.1007\/978-1-4614-5107-5","DOI":"10.1007\/978-1-4614-5107-5"},{"key":"2024102910301105000_94.9.738.7","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001032","article-title":"Argonaute autoantibodies as biomarkers in autoimmune neurologic diseases","volume":"8","author":"Do","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024102910301105000_94.9.738.8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318296e917"},{"key":"2024102910301105000_94.9.738.9","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00415-017-8583-z","article-title":"Mog antibody-related disorders: common features and uncommon presentations","volume":"264","author":"Cobo-Calvo","year":"2017","journal-title":"J Neurol"},{"key":"2024102910301105000_94.9.738.10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/08916934.2010.499886","article-title":"Anti-argonaute2 (ago2\/su) and -ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS)","volume":"44","author":"Ceribelli","year":"2011","journal-title":"Autoimmunity"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2022-330707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T17:30:25Z","timestamp":1730223025000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2022-330707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":10,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,26]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/jnnp-2022-330707"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2022-330707","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,21]]}}}